 | Hi Renukaprasad A R, | Antiplatelet therapy remains the standard of care in secondary stroke prevention for non-cardioembolic ischemic stroke and transient ischemic attack.
| The newer antiplatelet Ticagrelor with more potent and consistent antiplatelet effects has indicated superiority in reduction in the risk of the primary endpoints.
| | In this video, Dr. Gaurav Agrawal discusses ACS in Indian scenario and PLATO evidence, DAPT extension and Pegasus trial, Pharmaco-invasive approach-TREAT trial, SAPT emerging evidence and global leader. | | | | | | | | If you don't want to receive these emails in the future, please unsubscribe. | | | | |
.gif "add docplexus to primary")
No comments:
Post a Comment